Norditropin Daily denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

UHC's "not-FDA-approved" denial for Norditropin daily is one of the most procedurally fragile denials in the growth hormone vertical because Novo Nordisk's somatropin label is broader than most adjudicators realize. Under UHC's Commercial Medical Benefit Drug Policy for Human Growth Hormone (Somatropin) — which governs Norditropin alongside Genotropin, Humatrope, Nutropin AQ, Omnitrope, Saizen, and Zomacton — the FDA-approved indications explicitly include Pediatric GHD, Adult GHD, Turner syndrome, Noonan syndrome, SHOX deficiency, SGA without catch-up by age 2–4, and Idiopathic Short Stature with height SDS <-2.25. If your prescription falls within any of these, the "not FDA-approved" basis collapses on Optum medical review.

Procedural channel. Norditropin is administered under UHC's medical benefit, not OptumRx pharmacy benefit, so appeals route through Optum Medical Benefit Drug Appeals — not OptumRx. Submitting through the wrong queue adds 7–14 days. Use the UHC Provider Portal Specialty Pharmacy/Medical Benefit Drug authorization queue and reference the exact policy version from UHC's quarterly revision cycle.

Federal framing. 21 USC §333(e) criminalizes HGH distribution for non-FDA-approved uses — this is the statute UHC leans on to reflexively deny. Counter it by quoting Norditropin's USPI Section 1 verbatim and attaching the FDA approval letter. Under 29 CFR §2560.503-1(g)(1)(v)(B), UHC must specify the scientific/clinical judgment supporting denial; a bare "not FDA-approved" notice violates this ERISA disclosure rule and is your first procedural objection. For ACA-regulated commercial plans, also invoke 45 CFR §156.122(c) covering exceptions for medically necessary non-formulary or restricted drugs.

Case law. Pinto v. Aetna Life Ins. Co. (10th Cir. 2014) holds that under ERISA, the burden to demonstrate a treatment is experimental or non-approved rests on the plan administrator, not the claimant. UHC cannot shift that burden by citing internal medical policy as if it were FDA labeling.

Adult GHD documentation. Attach biochemical confirmation — Insulin Tolerance Test peak GH <5 ng/mL is UHC's test of choice; glucagon stimulation is acceptable when ITT is contraindicated. Endocrinologist coordination is required; primary-care prescribing is the second most common reason an FDA-approved indication gets miscoded as off-label.

External review. If internal appeal fails, ACA external review under 29 CFR §2590.715-2719 binds UHC to an IRO decision within 45 days (72 hours expedited). UHC Medicare Advantage members escalate to MAXIMUS Federal Services IRE under 42 CFR §422.566, then ALJ.

Tactical tip: File the appeal naming the exact FDA-approved indication, attach the Norditropin USPI, IGF-1, peak GH on stim test, bone age, and height SDS, and request peer-to-peer directly with UHC's endocrinology medical director — not the generalist reviewer. P2P resolution on properly documented FDA-labeled indications exceeds 70% on first contact.